FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:70-76 July 8, 1999 Number 2 Next

	Full Text PDF Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Percutaneous coronary revascularization is widely used in improving symptoms and exercise performance in patients with ischemic heart disease and stable angina pectoris. In this study, we compared percutaneous coronary revascularization with lipid-lowering treatment for reducing the incidence of ischemic events.

Methods We studied 341 patients with stable coronary artery disease, relatively normal left ventricular function, asymptomatic or mild-to-moderate angina, and a serum level of low-density lipoprotein (LDL) cholesterol of at least 115 mg per deciliter (3.0 mmol per liter) who were referred for percutaneous revascularization. We randomly assigned the patients either to receive medical treatment with atorvastatin, at 80 mg per day (164 patients), or to undergo the recommended percutaneous revascularization procedure (angioplasty) followed by usual care, which could include lipid-lowering treatment (177 patients). The follow-up period was 18 months.

Results Twenty-two (13 percent) of the patients who received aggressive lipid-lowering treatment with atorvastatin (resulting in a 46 percent reduction in the mean serum LDL cholesterol level, to 77 mg per deciliter [2.0 mmol per liter]) had ischemic events, as compared with 37 (21 percent) of the patients who underwent angioplasty (who had an 18 percent reduction in the mean serum LDL cholesterol level, to 119 mg per deciliter [3.0 mmol per liter]). The incidence of ischemic events was thus 36 percent lower in the atorvastatin group over an 18-month period (P=0.048, which was not statistically significant after adjustment for interim analyses). This reduction in events was due to a smaller number of angioplasty procedures, coronary-artery bypass operations, and hospitalizations for worsening angina. As compared with the patients who were treated with angioplasty and usual care, the patients who received atorvastatin had a significantly longer time to the first ischemic event (P=0.03).

Conclusions In low-risk patients with stable coronary artery disease, aggressive lipid-lowering therapy is at least as effective as angioplasty and usual care in reducing the incidence of ischemic events.

Source Information

From the Department of Medicine, University of Michigan School of Medicine, Ann Arbor (B.P.); the Division of Cardiology, Hartford Hospital, Hartford, Conn. (D.W.); the Department of Medicine, Emory University School of Medicine, Atlanta (W.V.B.); Thoraxcentre, University Hospital, Groningen, the Netherlands (A.J.B.); the Department of Medicine, Toronto Hospital, Toronto (L. Schwartz); the Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, N.S. (L.M.T.); Providence Saint Joseph Medical Center, Los Angeles (D.E.); and Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Mich. (L. Shurzinske, L.S.M.).

Address reprint requests to Dr. Pitt at the Division of Cardiology, University of Michigan Medical Center, 3910 Taubman, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0366, or at bpitt{at}umich.edu.

Full Text of this Article

Related Letters:

Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease
Cohen D. J., Carrozza J. P., Baim D. S., Ricciardi M. J., Davidson C. J., Bloom J. M., Pitt B., Waters D., Brown W. V.
Extract | Full Text  
N Engl J Med 1999; 341:1853-1855, Dec 9, 1999. Correspondence

This article has been cited by other articles:

• Schomig, A., Mehilli, J., de Waha, A., Seyfarth, M., Pache, J., Kastrati, A. (2008). A Meta-Analysis of 17 Randomized Trials of a Percutaneous Coronary Intervention-Based Strategy in Patients With Stable Coronary Artery Disease. J Am Coll Cardiol 52: 894-904 [Abstract] [Full Text]  
• Weintraub, W. S., Boden, W. E., Zhang, Z., Kolm, P., Zhang, Z., Spertus, J. A., Hartigan, P., Veledar, E., Jurkovitz, C., Bowen, J., Maron, D. J., O'Rourke, R., Dada, M., Teo, K. K., Goeree, R., Barnett, P. G., on Behalf of the Department of Veterans Affairs Co, (2008). Cost-Effectiveness of Percutaneous Coronary Intervention in Optimally Treated Stable Coronary Patients. Circ Cardiovasc Qual Outcomes 1: 12-20 [Abstract] [Full Text]  
• Weintraub, W. S., Spertus, J. A., Kolm, P., Maron, D. J., Zhang, Z., Jurkovitz, C., Zhang, W., Hartigan, P. M., Lewis, C., Veledar, E., Bowen, J., Dunbar, S. B., Deaton, C., Kaufman, S., O'Rourke, R. A., Goeree, R., Barnett, P. G., Teo, K. K., Boden, W. E., the COURAGE Trial Research Group, (2008). Effect of PCI on Quality of Life in Patients with Stable Coronary Disease. NEJM 359: 677-687 [Abstract] [Full Text]  
• Holmes, D. R. Jr, Gersh, B. J., Whitlow, P., King, S. B. III, Dove, J. T. (2008). Percutaneous Coronary Intervention for Chronic Stable Angina: A Reassessment. J Am Coll Cardiol Intv 1: 34-43 [Abstract] [Full Text]  
• Brown, M. L., Sundt, T. M. III, Gersh, B. J. (2008). Indications for Revascularization. Card Surg Adult 3: 551-572 [Full Text]  
• Cheng, S., Jarcho, J. (2007). Management of Stable Coronary Disease -- Polling Results. NEJM 357: e28-e28 [Full Text]  
• Kereiakes, D. J., Teirstein, P. S., Sarembock, I. J., Holmes, D. R. Jr, Krucoff, M. W., O'Neill, W. W., Waksman, R., Williams, D. O., Popma, J. J., Buchbinder, M., Mehran, R., Meredith, I. T., Moses, J. W., Stone, G. W. (2007). The Truth and Consequences of the COURAGE Trial. J Am Coll Cardiol 50: 1598-1603 [Abstract] [Full Text]  
• Bax, J. J., Young, L. H., Frye, R. L., Bonow, R. O., Steinberg, H. O., Barrett, E. J. (2007). Screening for Coronary Artery Disease in Patients With Diabetes. Diabetes Care 30: 2729-2736 [Abstract] [Full Text]  
• Lipson, A. H., Fallis, W. M., Wang, X., Yi, Y. (2007). Are patients with hyperlipidemia undertreated?: Study of patients admitted to hospital with coronary events. cfp 53: 1502-1507 [Abstract] [Full Text]  
• Lin, G. A., Dudley, R. A., Redberg, R. F. (2007). Cardiologists' Use of Percutaneous Coronary Interventions for Stable Coronary Artery Disease. Arch Intern Med 167: 1604-1609 [Abstract] [Full Text]  
• Stein, E. A. (2007). Statins and Children: Whom Do We Treat and When?. Circulation 116: 594-595 [Full Text]  
• Scolari, F., Ravani, P., Gaggi, R., Santostefano, M., Rollino, C., Stabellini, N., Colla, L., Viola, B. F., Maiorca, P., Venturelli, C., Bonardelli, S., Faggiano, P., Barrett, B. J. (2007). The Challenge of Diagnosing Atheroembolic Renal Disease: Clinical Features and Prognostic Factors. Circulation 116: 298-304 [Abstract] [Full Text]  
• Merhige, M. E., Breen, W. J., Shelton, V., Houston, T., D'Arcy, B. J., Perna, A. F. (2007). Impact of Myocardial Perfusion Imaging with PET and 82Rb on Downstream Invasive Procedure Utilization, Costs, and Outcomes in Coronary Disease Management. JNM 48: 1069-1076 [Abstract] [Full Text]  
• Pijls, N. H.J., van Schaardenburgh, P., Manoharan, G., Boersma, E., Bech, J.-W., van't Veer, M., Bar, F., Hoorntje, J., Koolen, J., Wijns, W., de Bruyne, B. (2007). Percutaneous Coronary Intervention of Functionally Nonsignificant Stenosis: 5-Year Follow-Up of the DEFER Study. J Am Coll Cardiol 49: 2105-2111 [Abstract] [Full Text]  
• Hochman, J. S., Steg, P. G. (2007). Does Preventive PCI Work?. NEJM 356: 1572-1574 [Full Text]  
• Boden, W. E., O'Rourke, R. A., Teo, K. K., Hartigan, P. M., Maron, D. J., Kostuk, W. J., Knudtson, M., Dada, M., Casperson, P., Harris, C. L., Chaitman, B. R., Shaw, L., Gosselin, G., Nawaz, S., Title, L. M., Gau, G., Blaustein, A. S., Booth, D. C., Bates, E. R., Spertus, J. A., Berman, D. S., Mancini, G.B. J., Weintraub, W. S., the COURAGE Trial Research Group, (2007). Optimal Medical Therapy with or without PCI for Stable Coronary Disease. NEJM 356: 1503-1516 [Abstract] [Full Text]  
• Patel, T. N., Shishehbor, M. H., Bhatt, D. L. (2007). A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis. Eur Heart J 28: 664-672 [Abstract] [Full Text]  
• Mahmarian, J. J., Dakik, H. A., Filipchuk, N. G., Shaw, L. J., Iskander, S. S., Ruddy, T. D., Keng, F., Henzlova, M. J., Allam, A., Moye, L. A., Pratt, C. M., for the INSPIRE Investigators, (2006). An Initial Strategy of Intensive Medical Therapy Is Comparable to That of Coronary Revascularization for Suppression of Scintigraphic Ischemia in High-Risk But Stable Survivors of Acute Myocardial Infarction. J Am Coll Cardiol 48: 2458-2467 [Abstract] [Full Text]  
• Gibbons, R. J., Miller, T. D. (2006). Noninvasive Risk Stratification After Myocardial Infarction: New Evidence, New Questions. J Am Coll Cardiol 48: 2468-2470 [Full Text]  
• Dzau, V. J., Antman, E. M., Black, H. R., Hayes, D. L., Manson, J. E., Plutzky, J., Popma, J. J., Stevenson, W. (2006). The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease). Circulation 114: 2850-2870 [Full Text]  
• Bonovas, S., Filioussi, K., Tsavaris, N., Sitaras, N. M. (2006). Statins and Cancer Risk: A Literature-Based Meta-Analysis and Meta-Regression Analysis of 35 Randomized Controlled Trials. JCO 24: 4808-4817 [Abstract] [Full Text]  
• Kennedy, D. J., Burket, M. W., Khuder, S. A., Shapiro, J. I., Topp, R. V., Cooper, C. J. (2006). Quality of life improves after renal artery stenting.. Biol Res Nurs 8: 129-137 [Abstract]  
• Smith, P. K., Califf, R. M., Tuttle, R. H., Shaw, L. K., Lee, K. L., Delong, E. R., Lilly, R. E., Sketch, M. H. Jr, Peterson, E. D., Jones, R. H. (2006). Selection of surgical or percutaneous coronary intervention provides differential longevity benefit.. Ann. Thorac. Surg. 82: 1420-1429 [Abstract] [Full Text]  
• Authors/Task Force Members, , Fox, K., Garcia, M. A. A., Ardissino, D., Buszman, P., Camici, P. G., Crea, F., Daly, C., De Backer, G., Hjemdahl, P., Lopez-Sendon, J., Marco, J., Morais, J., Pepper, J., Sechtem, U., Simoons, M., Thygesen, K., ESC Committee for Practice Guidelines (CPG), , Priori, S. G., Blanc, J.-J., Budaj, A., Camm, J., Dean, V., Deckers, J., Dickstein, K., Lekakis, J., McGregor, K., Metra, M., Morais, J., Osterspey, A., Tamargo, J., Zamorano, J. L., Document Reviewers, , Zamorano, J. L, Andreotti, F., Becher, H., Dietz, R., Fraser, A., Gray, H., Antolin, R. A. H., Huber, K., Kremastinos, D. T., Maseri, A., Nesser, H.-J., Pasierski, T., Sigwart, U., Tubaro, M., Weis, M. (2006). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 27: 1341-1381 [Full Text]  
• Wong, K Y K, McSwiggan, S, Kennedy, N S J, MacWalter, R S, Struthers, A D (2006). B-type natriuretic peptide identifies silent myocardial ischaemia in stroke survivors. Heart 92: 487-489 [Abstract] [Full Text]  
• Nash, D. T. (2005). The Case for Medical Treatment in Chronic Stable Coronary Artery Disease. Arch Intern Med 165: 2587-2589 [Full Text]  
• King, S. B. III (2005). Angioplasty Is Better Than Medical Therapy for Alleviating Chronic Angina Pectoris. Arch Intern Med 165: 2589-2592 [Full Text]  
• King, S. B. III (2005). Rebuttal. Arch Intern Med 165: 2593-2594 [Full Text]  
• Abrams, J., Thadani, U. (2005). Therapy of Stable Angina Pectoris: The Uncomplicated Patient. Circulation 112: e255-e259 [Full Text]  
• Nashed, B., Yeganeh, B., HayGlass, K. T., Moghadasian, M. H. (2005). Antiatherogenic Effects of Dietary Plant Sterols Are Associated with Inhibition of Proinflammatory Cytokine Production in Apo E-KO Mice. J. Nutr. 135: 2438-2444 [Abstract] [Full Text]  
• Ong, H.T. (2005). The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98: 599-614 [Abstract] [Full Text]  
• Kawasaki, M., Sano, K., Okubo, M., Yokoyama, H., Ito, Y., Murata, I., Tsuchiya, K., Minatoguchi, S., Zhou, X., Fujita, H., Fujiwara, H. (2005). Volumetric Quantitative Analysis of Tissue Characteristics of Coronary Plaques After Statin Therapy Using Three-Dimensional Integrated Backscatter Intravascular Ultrasound. J Am Coll Cardiol 45: 1946-1953 [Abstract] [Full Text]  
• Katritsis, D. G., Ioannidis, J. P.A. (2005). Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis. Circulation 111: 2906-2912 [Abstract] [Full Text]  
• Mensah, K., Mocanu, M. M., Yellon, D. M. (2005). Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: A potential role for phosphatase and tensin homolog deleted on chromosome ten?. J Am Coll Cardiol 45: 1287-1291 [Abstract] [Full Text]  
• Authors/Task Force Members, , Silber, S., Albertsson, P., Aviles, F. F., Camici, P. G., Colombo, A., Hamm, C., Jorgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., Urban, P., Stone, G. W., Wijns, W. (2005). Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 26: 804-847 [Full Text]  
• Modest, G. A. (2005). Medical vs Surgical Management of Left Main Coronary Artery Disease. JAMA 293: 1060-1061 [Full Text]  
• Kim, J., Henderson, R. A., Pocock, S. J., Clayton, T., Sculpher, M. J., Fox, K. A.A., RITA-3 Trial Investigators, (2005). Health-related quality of life after interventional or conservative strategy in patients with unstable angina or non-ST-segment elevation myocardial infarction: One-year results of the third randomized intervention trial of unstable angina (RITA-3). J Am Coll Cardiol 45: 221-228 [Abstract] [Full Text]  
• Sabatine, M. S., Braunwald, E. (2005). Another look at the age-old question: Which came first, the elevated c-reactive protein or the atherothrombosis?. J Am Coll Cardiol 45: 244-245 [Full Text]  
• Bonetti, P. O., Kaiser, C., Zellweger, M. J., Grize, L., Erne, P., Schoenenberger, R. A., Pfisterer, M. E., TIME Investigators, (2005). Long-Term Benefits and Limitations of Combined Antianginal Drug Therapy in Elderly Patients with Symptomatic Chronic Coronary Artery Disease. J CARDIOVASC PHARMACOL THER 10: 29-37 [Abstract]  
• Curtis, J. P., Krumholz, H. M. (2004). Keeping the Patient in View: Defining the Appropriateness of Percutaneous Coronary Interventions. Circulation 110: 3746-3748 [Full Text]  
• Claude, J., Schindler, C., Kuster, G. M., Schwenkglenks, M., Szucs, T., Buser, P., Osswald, S., Kaiser, C., Gradel, C., Estlinbaum, W., Rickenbacher, P., Pfisterer, M., for the Trial of Invasive versus Medical therapy i, (2004). Cost-effectiveness of invasive versus medical management of elderly patients with chronic symptomatic coronary artery disease: Findings of the randomized trial of invasive versus medical therapy in elderly patients with chronic angina (TIME). Eur Heart J 25: 2195-2203 [Abstract] [Full Text]  
• Woodard, L. D., Kressin, N. R., Petersen, L. A. (2004). Is Lipid-Lowering Therapy Underused by African Americans at High Risk of Coronary Heart Disease Within the VA Health Care System?. Am. J. Public Health 94: 2112-2117 [Abstract] [Full Text]  
• Hanania, G, Cambou, J-P, Gueret, P, Vaur, L, Blanchard, D, Lablanche, J-M, Boutalbi, Y, Humbert, R, Clerson, P, Genes, N, Danchin, N, for the USIC 2000 Investigators, (2004). Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart 90: 1404-1410 [Abstract] [Full Text]  
• Koren, M. J., Hunninghake, D. B., the ALLIANCE Investigators, (2004). Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study. J Am Coll Cardiol 44: 1772-1779 [Abstract] [Full Text]  
• Tunon, J., Blanco-Colio, L. M., Martin-Ventura, J. L., Egido, J. (2004). Intensive treatment with statins and the progression of cardiovascular diseases: the beginning of a new era?. Nephrol Dial Transplant 19: 2696-2699 [Full Text]  
• Nissen, S. E. (2004). High-Dose Statins in Acute Coronary Syndromes: Not Just Lipid Levels. JAMA 292: 1365-1367 [Full Text]  
• Cannon, C. P. (2004). Revascularisation for everyone?. Eur Heart J 25: 1471-1472 [Full Text]  
• Wolber, T., Walther, C., Gielen, S., Mobius-Winkler, S., Hambrecht, R. (2004). Management of Stable Coronary Disease: Primum Nil Nocere * Response. Circulation 110: e65-e65 [Full Text]  
• Lazar, H. L. (2004). Role of statin therapy in the coronary bypass patient. Ann. Thorac. Surg. 78: 730-740 [Abstract] [Full Text]  
• Kaiser, C., Kuster, G. M., Erne, P., Amann, W., Naegeli, B., Osswald, S., Buser, P., Schlapfer, H., Brett, W., Zerkowski, H.-R., Schindler, C., Pfisterer, M., the TIME Investigators, (2004). Risks and benefits of optimised medical and revascularisation therapy in elderly patients with angina - on-treatment analysis of the TIME trial. Eur Heart J 25: 1036-1042 [Abstract] [Full Text]  
• Yokoyama, I., Inoue, Y., Moritan, T., Ohtomo, K., Nagai, R. (2004). Impaired myocardial vasodilatation during hyperaemic stress is improved by simvastatin but not by pravastatin in patients with hypercholesterolaemia. Eur Heart J 25: 671-679 [Abstract] [Full Text]  
• Hambrecht, R., Walther, C., Mobius-Winkler, S., Gielen, S., Linke, A., Conradi, K., Erbs, S., Kluge, R., Kendziorra, K., Sabri, O., Sick, P., Schuler, G. (2004). Percutaneous Coronary Angioplasty Compared With Exercise Training in Patients With Stable Coronary Artery Disease: A Randomized Trial. Circulation 109: 1371-1378 [Abstract] [Full Text]  
• Thadani, U. (2004). Current Medical Management of Chronic Stable Angina. J CARDIOVASC PHARMACOL THER 9: S11-S29 [Abstract]  
• Berger, P. (2004). Ranolazine and Other Antianginal Therapies in the Era of the Drug-Eluting Stent. JAMA 291: 365-367 [Full Text]  
• Rihal, C. S., Raco, D. L., Gersh, B. J., Yusuf, S. (2003). Indications for Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in Chronic Stable Angina: Review of the Evidence and Methodological Considerations. Circulation 108: 2439-2445 [Full Text]  
• Gadsby, R. (2003). Review: Diabetic dyslipidaemia -- the case for using statins. British Journal of Diabetes & Vascular Disease 3: 402-407 [Abstract]  
• Henderson, R. A., Pocock, S. J., Clayton, T. C., Knight, R., Fox, K. A. A., Julian, D. G., Chamberlain, D. A., Second Randomized Intervention Treatment of Angina, (2003). Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 42: 1161-1170 [Abstract] [Full Text]  
• Crea, F, Lanza, G A (2003). The elusive link between stenosis severity and prognosis in stable ischaemic heart disease. Heart 89: 961-962 [Full Text]  
• Friday, K. E. (2003). Aggressive Lipid Management for Cardiovascular Prevention: Evidence from Clinical Trials. Exp. Biol. Med. 228: 769-778 [Abstract] [Full Text]  
• Malik, I. (2003). JournalScan. Heart 89: 815-816 [Full Text]  
• Bloomgarden, Z. T. (2003). Inflammation and Insulin Resistance. Diabetes Care 26: 1922-1926 [Full Text]  
• Scolari, F., Ravani, P., Pola, A., Guerini, S., Zubani, R., Movilli, E., Savoldi, S., Malberti, F., Maiorca, R. (2003). Predictors of Renal and Patient Outcomes in Atheroembolic Renal Disease: A Prospective Study. J. Am. Soc. Nephrol. 14: 1584-1590 [Abstract] [Full Text]  
• Chaturvedi, S. (2003). Should the Multicenter Carotid Endarterectomy Trials Be Repeated?. Arch Neurol 60: 774-775 [Full Text]  
• Thompson, P. D., Clarkson, P., Karas, R. H. (2003). Statin-Associated Myopathy. JAMA 289: 1681-1690 [Abstract] [Full Text]  
• Wong, K Y K, Walter, R S M., Douglas, D, Fraser, H W, Ogston, S A, Struthers, A D (2003). Long QTc predicts future cardiac death in stroke survivors. Heart 89: 377-381 [Abstract] [Full Text]  
• Lau, W. C., Waskell, L. A., Watkins, P. B., Neer, C. J., Horowitz, K., Hopp, A. S., Tait, A. R., Carville, D. G.M., Guyer, K. E., Bates, E. R. (2003). Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation: A New Drug-Drug Interaction. Circulation 107: 32-37 [Abstract] [Full Text]  
• Futterman, L. G., Lemberg, L. (2003). Seminal Changes in the Management of the Acute Coronary Event: Current Concepts. Am J Crit Care 12: 73-76 [Full Text]  
• Sundt, T. M. III, Gersh, B. J., Smith, H. C. (2003). Indications for Coronary Revascularization. Card Surg Adult 2: 541-559 [Full Text]  
• Pasternak, R. C. (2002). The ALLHAT Lipid Lowering Trial--Less Is Less. JAMA 288: 3042-3044 [Full Text]  
• Rashid, S., Uffelman, K. D., Barrett, P. H. R., Lewis, G. F. (2002). Effect of Atorvastatin on High-Density Lipoprotein Apolipoprotein A-I Production and Clearance in the New Zealand White Rabbit. Circulation 106: 2955-2960 [Abstract] [Full Text]  
• Martin, R M, Hemingway, H, Gunnell, D, Karsch, K R, Baumbach, A, Frankel, S (2002). Population need for coronary revascularisation: are national targets for England credible?. Heart 88: 627-633 [Abstract] [Full Text]  
• Flansbaum, B. E., Huddleston, J. M. (2002). Update in Hospital Medicine. ANN INTERN MED 137: 814-822 [Abstract] [Full Text]  
• Modest, G. A. (2002). Guidelines for the Management of Patients with Chronic Stable Angina. ANN INTERN MED 137: 548-549 [Full Text]  
• Young, N. S., Tisdale, J. F. (2002). High-Dose Cyclophosphamide for Treatment of Aplastic Anemia. ANN INTERN MED 137: 549-550 [Full Text]  
• Malik, I. (2002). JournalScan. Heart 88: 319-320 [Full Text]  
• Sculpher, M.J., Smith, D.H., Clayton, T., Henderson, R.A., Buxton, M.J., Pocock, S.J., Chamberlain, D.A. (2002). Coronary angioplasty versus medical therapy for angina. Health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. Eur Heart J 23: 1291-1300 [Abstract]  
• Danchin, N, Grenier, O, Ferrieres, J, Cantet, C, Cambou, J-P (2002). Use of secondary preventive drugs in patients with acute coronary syndromes treated medically or with coronary angioplasty: results from the nationwide French PREVENIR survey. Heart 88: 159-162 [Abstract] [Full Text]  
• Mark, D. B., Hlatky, M. A. (2002). Medical Economics and the Assessment of Value in Cardiovascular Medicine: Part II. Circulation 106: 626-630 [Full Text]  
• Keaney, J. F. Jr., Vita, J. A. (2002). The Value of Inflammation for Predicting Unstable Angina. NEJM 347: 55-57 [Full Text]  
• Kennedy, H. L., Rosenson, R. S. (2002). Physicians' interpretation of "class effects": A need for thoughtful re-evaluation. J Am Coll Cardiol 40: 19-26 [Abstract] [Full Text]  
• Kapur, A, Malik, I S (2002). Is surgery still the preferred option for coronary revascularisation in diabetics with multivessel coronary disease?. Heart 87: 407-409 [Full Text]  
• Kim, M. C., Kini, A., Sharma, S. K. (2002). Refractory angina pectoris: Mechanism and therapeutic options. J Am Coll Cardiol 39: 923-934 [Abstract] [Full Text]  
• Mannheimer, C., Camici, P., Chester, M.R., Collins, A., DeJongste, M., Eliasson, T., Follath, F., Hellemans, I., Herlitz, J., Luscher, T., Pasic, M., Thelle, D. (2002). The problem of chronic refractory angina. Report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J 23: 355-370 [Full Text]  
• Pearson, T. A. (2002). New Tools for Coronary Risk Assessment: What Are Their Advantages and Limitations?. Circulation 105: 886-892 [Abstract] [Full Text]  
• Schaefer, E. J (2002). Lipoproteins, nutrition, and heart disease. Am. J. Clin. Nutr. 75: 191-212 [Abstract] [Full Text]  
• Kreisberg, R. A., Oberman, A. (2002). Lipids and Atherosclerosis: Lessons Learned from Randomized Controlled Trials of Lipid Lowering and Other Relevant Studies. J. Clin. Endocrinol. Metab. 87: 423-437 [Full Text]  
• Brorsson, B, Bernstein, S J, Brook, R H, Werko, L (2002). Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart 87: 140-145 [Abstract] [Full Text]  
• Waters, D. D., Hsue, P. Y. (2001). Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease: Treating Between the Lines. Circulation 104: 2635-2637 [Full Text]  
• Malik, J., Melenovsky, V., Wichterle, D., Haas, T., Simek, J., Ceska, R., Hradec, J. (2001). Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial -- FAT). Cardiovasc Res 52: 290-298 [Abstract] [Full Text]  
• Cleland, J. G F, John, J., Dhawan, J., Clark, A. (2001). What is the optimal medical management of ischaemic heart failure?. Br Med Bull 59: 135-158 [Abstract] [Full Text]  
• Braunstein, J. B., Cheng, A., Cohn, G., Aggarwal, M., Nass, C. M., Blumenthal, R. S. (2001). Lipid Disorders : Justification of Methods and Goals of Treatment. Chest 120: 979-988 [Abstract] [Full Text]